European Journal of Cancer

Article	Citations
The impossibility of mortality evaluation of skin cancer screening in Germany based on health insurance data: a case–control study	404
Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome	250
Onco-functional outcome after resection for eloquent glioblastoma (OFO): A propensity-score matched analysis of an international, multicentre, cohort study	183
Gut microbiome and immune checkpoint inhibitor toxicity	173
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database	165
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial	144
Editorial Board	144
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONA	142
Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal ca	142
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model	142
Editorial Board	133
Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial	130
“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools	125
The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project	120
Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer	107
Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial	106
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	99
Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC/UICC TNM staging system in the immunotherapy era: A multicenter cohort study	96
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma	95
Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes	93
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	92
Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors	90
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial	90
Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study	87
Artificial intelligence-assisted probability scoring for differentiation of early mycosis fungoides and benign inflammatory dermatoses on H&E stained pathology slides of skin biopsies	84

Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	82
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	82
Cancer and immunotherapy: a role for microbiota composition	80
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies	80
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers	79
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	77
Troponin increase during immunotherapy: Not always myocarditis	75
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical tria	75
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	73
Gene expression-based prediction of pazopanib efficacy in sarcoma	69
Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis	69
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	68
The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer	67
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial	66
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inh	65
Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study	64
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	63
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	62
Kidney function assessment for eligibility in clinical cancer trials – Data from the European Organisation for Research and Treatment of Cancer	62
Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma	60
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting	60
Editorial Board	60
Editorial Board	58
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	58
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB	58
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression	57
Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing	56
False-Negative Rates Between Pathological Lymph Node Status Between Ductal and Lobular Breast Cancer: A Retrospective Cohort Study of 83,152 Patients	56
Editorial Board	56
Spatial Immunophenotyping Identifies Differential Infiltration of Immunosuppressive Subsets in Tumor Stroma and Invasive Margin and PDL1 expression in Inflammatory and non-Inflammatory Breast Cancer P	55
Surgical choices and complications in elderly women: a single center retrospective analysis in frail vs non frail breast cancer patients	55
PAM50 genomic test in the management of early breast cancer – the importance of clinical-pathological data	54
Sonographic assessment of the axilla in breast cancer: changing the threshold	54
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	54
A retrospective evaluation of factors associated with upstage to malignancy for breast lesions of uncertain malignant potential (B3): findings from an American cohort	54
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	53
Author Index	53
Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer	51
STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset	51
CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors	51
NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma	51
Impact of orthotopic versus subcutaneous implantation on patient-derived xenograft transcriptomic profile	51
Adding metabolic agents to prostate cancer therapy: Every rose has its thorn	51
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults	51
Cutaneous manifestation of mature plasmacytoid dendritic cell proliferation in patients with myeloid leukemia	51
A novel dual PARP-HDAC inhibitor for treatment of Ewing sarcoma	50
Covalent pan-TEAD inhibitors for the treatment of cancers with Hippo pathway alterations	50
First-in-class heterobifunctional proteomimetic polymer capable of direct inhibition of Myc and target it for degradation	50
Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative brea	50
KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers	49

Advances in the development of a targeted N-Terminal Domain androgen receptor (AR) degrader (ANITAC) for the treatment of prostate cancer	48
Cutaneous relapses location in diffuse large B-cell lymphoma leg type after immunochemotherapy	48
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	48
SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients	48
CCR8 expression as a potential diagnostic and therapeutic biomarker in cutaneous T-cell lymphoma	48
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	47
Single-cell RNA sequencing characterization of primary cutaneous B-cell lymphomas with their systemic counterparts	47
CD8 positive Sézary syndrome: two cases	47
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	47
Combination Therapy with Poly-gamma-glutamic Acid and Anti-PD-1 Results in Synergistic Therapeutic Effects against Cancers	46
ERK3/MAPK6 has a dual role as pro-and anti-tumorigenic in Triple-Negative Breast Cancer	46
Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in tumour tissue	45
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	45
NUC-3373 induces DAMPs release from NSCLC cells potentiating a favourable immunogenic microenvironment	45
Treatment strategies based on the molecular subtypes of transformed small cell lung cancer (t-SCLC)	44
The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds	44
High-Throughput Screening Identifies Novel ROS-Inducing Small Molecules as a Therapy for Treatment-Resistant Melanoma	44
HR-LiP, a novel structural proteomics approach for the prediction of small molecule drug-protein binding events	44
Molecular crosstalk between NF-κB and NRF2 signaling affects prognosis in HPV-associated head and neck cancer	44
The anti-CD205 antibody drug conjugate MEN1309/OBT076 shows synergistic activity in combination with the monoclonal antibody rituximab in diffuse large B cell lymphomas	44
Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors	43
Axitinib-related cardiac dysfunction occurring after resumption of treatment	43
Targeting the exosome biogenesis pathway to overcome daratumumab resistance in hematological cancers	43
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma	43
Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer	43
Discovery of Essential microRNA in Prostate Cancer Cells	42
Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML	42
Preliminary results from HERKULES-1: a phase 1b/2, open-label, multicenter study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors	42
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	42
Developing a preclinical CD47 IHC assay using patient-like samples for the development of a companion diagnostic for CD47-targeting treatments	42
Epithelial-Mesenchymal plasticity mediates acquired resistance to eribulin in breast cancer	42
Design and development of an innovative, safe, and highly potent E1 ubiquitin-activating enzyme inhibitor CPL–410-005 conjugate in anticancer therapy	42
HORMAD1 drives spindle assembly checkpoint defects and sensitivity to multiple mitotic kinases	41
Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit	41
Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus	41
Neutralizing antibody for S100A8/A9 soil sensing signal to prevent metastatic disease	41
Differentiating lymphocytic hypereosinophilic syndrome from Sézary syndrome using transcriptomic analysis	41
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	41
Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome	40
Combination of JAKi and HDACi as a potential anti-angiogenic treatment in a cutaneous T-cell lymphoma (CTCL) in vivo chick embryo model	40
DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a	40
Re-treatment approaches in patients with cutaneous-T-cell lymphoma: a real-life experience	40
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	40
Activity and safety of ipatasertib (ipat) for AKT activating mutation and/ or PTEN loss/loss of function solid tumors from MyTACTIC	40
A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients tre	40
rOPCML-Fc as a potential tumor suppressive therapeutic agent for ovarian cancer	39
Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer cells	39
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	39
Real-world effectiveness of mogamulizumab in patients with Sézary syndrome or mycosis fungoides in Spain and Portugal: The MIBERIC study	39
Non-invasive digital disease severity scoring compared to CAILS in early-stage mycosis fungoides	38
The combination of the metabolism-based targeted therapies ADI-PEG20 and GC7 are a promising strategy for the treatment of malignant pleural mesothelioma	38
The value of digital PCR-based quantification of DNA methylation biomarkers in diagnostic challenging early Sézary syndrome patients	38
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	38
Polyamine transport inhibition with AMXT-1501 synergizes with cisplatin in HNSCC	38
Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53	38
Anticancer activity of (±)-kusunokinin derivatives as a new HSP90 inhibitor	38
Table of Contents	38
Transcriptome and computational analysis assess the anti-tubulin activity of [1,2]oxazole derivatives in lymphoma	38
Transcriptomic profiling to identify key players of Ewing Sarcoma metastasis	37
Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study	37
Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile	37
A novel anti-cancer compound development targeting YAP-TEAD protein-protein interaction	37
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	36
Response of Human and Canine Tumor Cell Lines to Pharmacologic and Genetic Autophagy Inhibition	36
Copyright Page	36
The novel, telomerase-directed, telomere-targeted, anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models	36
A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors	36
CAR-T cell engineering strategies aimed at safe and effective targeting of solid tumors	36
Ex vivo harmonic generation microscopy assessment in cutaneous T-cell lymphomas diagnosis	36
NP-G2-044, a First-in-Class Fascin Inhibitor, Inhibits Growth and Metastasis of Gynecologic Cancers	36
6-gingerol Suppresses Angiogenesis and Promotes T-cell cytotoxicity in Mice Model of Colorectal Cancer	35
Establishment and characterization of HPV+ metastatic squamous cell anal carcinoma XPDX models in athymic nude mice	35
Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration, restricts the development and metastasis of solid malignancies and improves their response to immunotherapy	35
Non-clinical identification and characterization of KRAS G12D inhibitors	35
Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies	35
Letter Re: Survival trends in solid cancers in the Nordic countries through 50 years	34
Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctD	34
Response to letter entitled: Re: ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial’	34
Letter re: “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”	34
PIN-A1, a novel Casein Kinase 1α-selective molecular glue degrader, demonstrates strong antitumor activity via activation of the p53 pathway in preclinical models of AML with a favorable safety profil	34

A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases	33
Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia—results of a double-blind, randomised controlled trial with cross-over de	33
Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy	33
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma	33
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data	33
Regression of intestinal diffuse large B cell lymphoma after treatment with vedolizumab in a patient with Crohn's disease	33
Response to letter Re: Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies	33
Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!	33
Preoperative MRI in women with newly diagnosed breast cancer: re-excision rates and additional findings	32
Retrospective thorough analysis of regional lymph node recurrence in breast cancer patients (REASON Trial)	32
The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review	32
Unusual ocular manifestations of breast carcinoma: A single institute case series in the Indian population	32
Advanced breast cancer journey: a consensus guidance from a multidisciplinary panel for improving clinical practice in Portugal	32
Factors affecting Quality of Life among breast cancer survivors	32
Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: a survey within the MINDACT cohort	32
Shared decision-making in breast cancer care: Evidence from a scoping literature review and a survey across breast units in Europe	32
Myalgias upon PD-1 checkpoint blockade: Think of immunotherapy induced hypothyroid myopathy	31
Causes and consequences of delayed diagnosis in breast cancer screening; focus on mammographic features and tumour characteristics	31
Predictive factors of macrometastasis in sentinel lymph node in invasive lobular carcinoma	31
Short-term surgical complications of skin-sparing mastectomy and direct-to-implant immediate breast reconstruction in women concurrently treated with adjuvant radiotherapy for breast cancer (2022; arc	31
Margin status and Survival outcomes following breast conservation surgery: a metaanalysis	31
Re: Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy	30
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	30
Fluorescence guided fully endoscopic axillary dissection for locally advanced breast cancer. A feasible novel technique	30
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomise	30
How ‘breast aware’ are the Indian women? A study among the women visiting a tertiary-care, referral and teaching hospital	30
Anxiety and depression screening during neoadjuvant chemotherapy treatment in early breast cancer patients: a multicenter longitudinal observational study	30
Breast cancer nutritional risk factors: insights from the Tesco 1.0 dataset	30
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	30
MINIVAB trial: Minimally invasive breast cancer excision using vacuum assisted biopsy under ultrasound guidance	29
The mediating effect of perceived injustice and pain catastrophizing in the relationship of pain on fatigue and sleep in breast cancer survivors: a cross-sectional study	29
The value of palpation, US and NMR in staging of axilla in patients with breast cancer in order to avoid unnecessary ALND	29
Epigenetic silencing of P16INK4a hasten disease stage in Carcinoma of Breast: A hospital-based study of North India	29
Forty-eight weeks of yogic intervention improves serum interleukins IL-10 and IL-1β along with fatigue and quality of life during the radiotherapy/chemotherapy in breast cancer patients: a randomized	29
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors	29
Cost-effectiveness of abemaciclib in early breast cancer patients: one size fits all or tailoring to patients’ needs	29
Ultrahypofractionated radiation therapy for breast cancer: two-year normal tissue effects	29
Breast cancer axillary dissection a “lost procedure, sometimes still necessary…” how to prevent the lost of a surgical technique using cadaver body and Simlife	29
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	29
Impact of breast cancer diagnosis on women’s sexuality	29
Clinical and sociodemographic determinants of disease-specific health-related quality of life in long-term breast cancer survivors	29
Accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with high-dose-rate brachytherapy (HDR)	29
Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis	29
Digital health applications to support patients with breast cancer: Effects of two tailored, dialogue-based programs on quality of life	28
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade	28
Impact of musical training in breast cancer patients with post-treatment cognitive, funtional and emotional sequelae	28
Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy after second conservative-surgery	28
Neoadjuvant treatment for breast cancer patients in a Venezuelan breast center. Pathologic complete response: is it worth it?	28
Anthracycline versus no anthracycline neoadjuvant therapy for HER2 breast cancer: real world evidence	27
A higher number of HSP70 positive immune cells in a deep layer of TNBC is associated with a higher FOXP3 expression and a higher risk of axillary lymph node involvement	27
Interobserver variation in the assessment of HER2 low expression in breast cancer: can we improve by adjusting criteria? An international interobserver study	27
Ineligible for transplant, but eligible for intensive quadruplet therapy—The value of ‘add-on’ trials for vulnerable patient populations	27
Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis	27
Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy	27
Cell-free DNA concentration in patients with different molecular subtypes of breast cancer	27
Assessment and management of lesions of uncertain malignant potential of the breast at Trieste Breast Unit: a single center experience	27
Home based care for terminal cancer patients: study from rural part of India	27
Clinical and Experimental investigation of AKT1/2/3 isoforms indicated non-redundant isoform specific role in driving stemness and Cisplatin resistance in TNBCs	27
Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity	27
The global, regional, and national disease burden of breast cancer attributable to tobacco from 1990 to 2019: a global burden of disease study	26
Results of ex vivo biopsies on explanted breast tissue	26
Impact of establishing a genetic clinic in conjunction with clinical practice in India	26
CXCR4/CXCL12 axis as a potential therapeutic target in mycosis fungoides: an in-vitro study	26
Patterns and prognostic significance of cutaneous immune-related adverse events in non–small cell lung cancer	26
Oncoplastic innovation: immediate prepectoral reconstruction using Braxon® – our experience	26
Contrast-enhanced mammography (CEM) with magnetic tracer as an alternative to MRI	26
Papuloerythroderma of Ofuji successfully treated with oral retinoids	26
A prospective comparative study of indocyanine green, radioisotope, and methylene blue for sentinel lymph node detection in early breast cancer: Evaluating sensitivity, oncological safety, and patient	26
Enhanced cancerous properties of breast cancer cell and brown adipocyte co-cultures compared to their fused cells	26
Editorial Board	26
10-year survival outcomes of following ultrasound-guided targeted axillary surgery in breast cancer patients after neoadjuvant chemotherapy	26
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry	25
Quality assurance of radiation therapy among patients in the BOOG 2013-08 trial	25
Patient-reported outcomes of clinical importance during five years after breast cancer diagnosis using real world data	25
Cold heart: active breathing coordinator-assisted deep inspiration breath hold leads to a safer heart sparing approach to early and locally advanced breast cancer treatment	25
Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer	25
Large cell transformation is an independent prognostic factor in Sézary syndrome: a retrospective analysis of 117 cases	25
Cutaneous and systemic lymphomas of concordant or discordant B- and T-cell phenotype in the same patient: two case reports	25
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities	25
Indolent primary cutaneous T-cell gamma delta lymphomas: a first illustrated series of 5 cases	25
Geriatric-8 as a screening tool in elderly breast cancer patients for prediction of mortality in Indian cohort	25
Multimodal Predictive Modelling for Axillary Nodal Involvement: Integrating Pathology and Clinicopathological EUSOMA Data	25
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies	25
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	25
SARS-CoV-2 M-protein promotes malignancy of breast cancer cells and alters interaction in breast tumor microenvironment	24
Interrogating HER2 status in Circulating Tumor Cells isolated using the Parsortix® System from Metastatic Breast Cancer patients	24
[18F]FDG whole-body PET-MR including an integrated breast MR protocol for locoregional and distant staging in breast cancer patients – a feasibility study	24
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas	24
Macular type of primary cutaneous B-cell lymphoma: extension of the clinical and histopathological patterns	24
Evaluation of mir-146a and mir-155 plasma expression levels in patients with mycosis fungoides and detection of single nucleotide polymorphisms in their sequence	24
Racial differences in clinical presentation and outcomes in mycosis fungoides and Sézary syndrome in the United States: a large singe center retrospective analysis	24
Mutation spectrum of homologous recombination repair genes in early triple-negative breast cancer: association with clinicopathological factors, immune infiltration, and prognosis	24
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma	24
An update on health-related quality of life from the PROCLIPI study	24
Next-generation sequencing reveals tumour origin in a patient with rare metachronous colonic metastasis from pancreatic cancer	24